For You
The National Cancer Institute
Treatment
The National Cancer Institute
Cancer Genetics Branch
Investigators in the Cancer Genetics Branch (CGB) seek to identify and study genes that contribute to cancer susceptibility and progression. CGB investigators are zeroing in on inherited mutations that contribute to the development of various aggressive cancers, including sarcomas and prostate, breast, and kidney cancers. They also are interested in understanding the relationship between genetic variation and cancer progression and in finding germline variants that lead, specifically, to fast-growing, aggressive tumors.
The susceptibility many types of cancers is largely inherited or results from an accumulation of genetic changes in a number of genes occurring over time. Environmental exposures also may play a significant role. To better elucidate these complex biological processes, CGB investigators are both developing new technologies and exploiting existing methods. They are particularly interested in comparative approaches and have, together with their collaborators, constructed genetic and radiation hybrid maps of the dog genome. These maps have proven invaluable in understanding the genetics of complex disease shared by humans and their pets. Such discoveries have the potential to contribute to the development of new diagnostics and therapies for improving patient survival and well-being.
Senior Investigator
Elaine A. Ostrander, Ph.D.
Senior Investigator and Chief
Head, Comparative Genetics Section
Investigators
Daphne W. Bell, Ph.D.
Investigator
Head, Reproductive Cancer Genetics Section
Nigel Crawford, M.B. Ch.B., Ph.D.
Investigator
Head, Metastasis Genetics Section
Yardena Samuels, Ph.D.
Investigator
Head, Molecular Cancer Genetics Section
Associate Investigator
Settara C. Chandrasekharappa, Ph.D.
Associate Investigator
Head, Cancer Genetics Unit
Last Updated: March 2, 2010
